Comparison of hierarchy of risk of structural progression according to each classification by genotype analysis on ESPOIR and EAC cohorts
| ESPOIR | EAC | Meta-analysis | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | p Value | |
| Acid–base | ||||
| NN/NN, X/NN or XX referent | 1 | 1 | 1 | |
| A/A, A/NN or A/X | 0.30 (0.11 to 1.79) | 0.44 (0.18 to 1.10) | 0.37 (0.19 to 0.71) | 0.002 |
| BN/BN, BN/NN or BN/X | 1.10 (0.57 to 2.10) | 1.09 (0.57 to 2.04) | 1.09 (0.69 to 1.72) | 0.7 |
| A/BB | 1.78 (0.63 to 4.98) | 0.48 (0.14 to 1.65) | 0.99 (0.46 to 2.09) | 0.9 |
| BN/BB | 2.24 (1.03 to 4.83) | 1.80 (0.87 to 3.75) | 2.00 (1.17 to 3.39) | 0.009 |
| BB/BB | 3.50 (1.42 to 8.59) | 3.15 (1.12 to 8.80) | 3.34 (1.69 to 6.57) | <0.001 |
| De Vries | ||||
| P/P referent | 1 | 1 | 1 | – |
| P/N and N/N | 1.15 (0.47 to 2.83) | 1.33 (0.65 to 2.71) | 1.26 (0.72 to 2.20) | 0.4 |
| SE/P | 3.87 (1.61 to 9.33) | 2.74 (1.36 to 5.49) | 3.16 (1.84 to 5.45) | <0.0001 |
| SE/N | 4.00 (1.64 to 9.74) | 1.97 (0.96 to 4.04) | 2.67 (1.54 to 4.63) | 0.0005 |
| SE/SE | 5.12 (2.01 to 13.03) | 4.75 (2.12 to 10.68) | 4.92 (2.67 to 9.07) | <0.0001 |
| Mattey | ||||
| D70+/D70+ referent | 1 | 1 | 1 | – |
| D70+/D70− and D70−/D70− | 1.08 (0.52 to 2.28) | 1.54 (0.67 to 3.53) | 1.27 (0.73 to 2.21) | 0.4 |
| D70+/SE | 2.92 (1.47 to 5.80) | 3.23 (1.38 to 7.60) | 3.04 (1.78 to 5.19) | <0.0001 |
| D70−/SE | 5.26 (2.55 to 10.85) | 2.41 (1.05 to 5.51) | 3.72 (2.15 to 6.41) | <0.0001 |
| SE/SE | 4.81 (2.24 to 10.31) | 5.51 (2.18 to 13.95) | 5.08 (2.82 to 9.16) | <0.0001 |
| Du Montcel | ||||
| XX referent | 1 | 1 | 1 | – |
| S1/X and S1/S1 | 0.34 (0.10 to 1.20) | 0.47 (0.20 to 1.14) | 0.42 (0.21 to 0.87) | 0.02 |
| S3D/X and S3D/S3D | 0.22 (0.06 to 0.75) | 1.28 (0.45 to 3.68) | 0.62 (0.29 to 1.35) | 0.2 |
| S1/S2 and S1/S3P | 0.69 (0.26 to 1.83) | 0.78 (0.34 to 1.77) | 0.74 (0.40 to 1.39) | 0.4 |
| S3D/S2 and S3D/S3P | 0.68 (0.22 to 2.06) | 1.75 (0.64 to 4.79) | 1.14 (0.55 to 2.40) | 0.7 |
| S2/S2, S3P/S2 and S3P/S3P | 1.60 (0.63 to 4.07) | 2.89 (1.17 to 7.11) | 2.16 (1.13 to 4.13) | 0.02 |
| Reviron | ||||
| XP4n/XP4n referent | 1 | 1 | 1 | – |
| XP4n/XP4p and XP4p/XP4p | 1.74 (0.75 to 4.05) | 1.77 (0.75 to 4.20) | 1.76 (0.96 to 3.21) | 0.07 |
| XP4n/SE | 4.14 (1.83 to 9.38) | 3.53 (1.45 to 8.60) | 3.86 (2.12 to 7.05) | <0.001 |
| XP4p/SE | 2.78 (1.18 to 6.56) | 6.69 (2.88 to 15.57) | 4.38 (2.41 to 7.96) | <0.001 |
| SE/SE | 6.67 (2.76 to 16.08) | 6.20 (2.38 to 16.15) | 6.45 (3.38 to 12.34) | <0.001 |
95% CI.
BB, allele group containing basic AA at positions 13, 70 and 71; BN, allele group containing either a basic amino acid at position 13 and a neutral or acid and basic amino acid at positions 70 and 71 or a neutral amino acid at position 13 and a basic amino acid at positions 70 and 71; A, allele group containing acid amino acids at positions 70 and 71; NN, allele group with a neutral amino acid at position 13 and either a basic and an acidic amino acid at positions 70 and 71 or two neutral amino acids at positions 70 and 71; X, allele group not containing RAA sequence at positions 72–74; N, allele group not containing an isoleucine at position 67; P, allele group containing an isoleucine at position 67; SE, shared epitope; D70−, allele group not containing an aspartic acid at position 70; D70+, allele group containing an aspartic acid at position 70; XP4p, fourth pocket positively charged; XP4n, fourth pocket negatively or non-charged.